Effect of infliximab on small bowel stenoses in patients with Crohn's disease

World Journal of Gastroenterology

Volumn 14, Issue 12, 2008, Pages 1885-1890

  Pallotta, Nadia ^a   Barberani, Fausto ^a   Hassan, Naima Abdulkadir ^a   Guagnozzi, Danila ^a   Vincoli, Giuseppina ^a   Corazziari, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Crohn's disease; Infliximab; Intestinal stenosis

Indexed keywords

INFLIXIMAB; MACROGOL;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; ECHOGRAPHY; ENDOSCOPY; FEMALE; HUMAN; INTESTINE STENOSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SMALL INTESTINE CONTRAST ULTRASONOGRAPHY;

EID: 42149161097     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.1885     Document Type: Article

References (30)

1. Toy LS, Scherl EJ, Kornbluth A, Marion JF, Greenstein AJ, Agus S, Gerson C, Fox N, Present DH. Complete bowel obstruction following initial response to infliximab therapy for Crohn's disease: A series of a newly described complications. Gastroenterology 2000; 118: 2974
2. Vasilopoulos S, Kugathasan S, Saeian K, Emmons JE, Hogan WJ, Otterson MF, Telford CL, Binion DG. Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease. Am J Gastroenterol 2000; 95: 2503
3. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohns disease. Am J Gastroenterol 2006; 101: 1030-1038
4. Louis E, Collard A, Oger AF, Degroote F, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782
5. Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J Clin Gastroenterol 2003; 37: 216-219
6. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241
7. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250
8. Pallotta N, Baccini F, Corazziari E. Contrast ultrasonography of the normal small bowel. Ultrasound Med Biol 1999; 25: 1335-1340
9. Pallotta N, Baccini F, Corazziari E. Small intestine contrast ultrasonography. J Ultrasound Med 2000; 19: 21-26
10. Pallotta N, Tomei E, Viscido A, Calabrese F, Marcheggiano A, Caprilli R, Corazziari E. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005; 11: 146-153
11. Calabrese E, La Seta F, Buccellato A, Virdone R, Pallotta N, Corazziari E, Cottone M. Crohn's disease: a comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema. Tnflamm Bowel Dis 2005; 11: 139-145
12. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-697
13. Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis 2005; 20: 1-8
14. Barberani F, Boschetto S, Gigliozzi A, Giovannone M, Tosoni M. Safety and effectiveness of endoscopic pneumatic dilatation (EPD) + Infliximab combined therapy in stenosing Crohn's disese. Gastroenterology 2006; 130: A658
15. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999; 397: 710-713
16. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
17. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-28
18. Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, MacDonald TT. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-149
19. Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004; 10: 55-60
20. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol 1999; 277: C183-C201
21. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117: 814-822
22. Pender SL, MacDonald TT. Matrix metalloproteinases and the gut - new roles for old enzymes. Curr Opin Pharmacol 2004; 4: 546-550
23. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63-73
24. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, Boniver J, Belaiche J, Malaise M. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-246
25. Graham MF. Pathogenesis of intestinal strictures in Crohn's disease. Inflamm Bowel Dis 1995; 1: 220-227
26. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C172-C182
27. Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007; 56: 130-139
28. Sans M, Masamunt MC. Fibrogenesis and inflammatory bowel disease. Gastroenterol Hepatol 2007; 30: 36-41
29. Lawrance IC, Wu F, Leite AZ, Willis J, West CA, Fiocchi C, Chakravarti S. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003; 125: 1750-1761
30. Di Sabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment Pharmacol Ther 2004; 19: 1019-1024